In an effort to control healthcare costs, provide healthcare to the uninsured and underinsured, and improve health outcomes, there has been growing interest among politicians and the public
The disconnect between payers and pharma companies is just one symptom of pharma’s outdated business model, according to Janssen’s company group chairman EMEA, Kris Sterkens.
Alexander Gray and Mike Rea from IDEA Pharma explain why the current pharma R&D model is broken, and how it’s hindering commercialisation for companies across the industry
